Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
National Cancer Institute (NCI)
National Cancer Institute (NCI)
BeOne Medicines
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Genmab
Eli Lilly and Company
University of Iowa
Wake Forest University Health Sciences
Dragonfly Therapeutics
Eli Lilly and Company
Jonsson Comprehensive Cancer Center
Inhibrx Biosciences, Inc
Rutgers, The State University of New Jersey
Tyligand Pharmaceuticals (Suzhou) Limited
Mayo Clinic
University of Southern California
BeiGene
Innovent Biologics (Suzhou) Co. Ltd.
M.D. Anderson Cancer Center
Fox Chase Cancer Center
UNC Lineberger Comprehensive Cancer Center
ImmunityBio, Inc.
Purple Biotech Ltd.
Radiation Therapy Oncology Group
Merck Sharp & Dohme LLC
Vanderbilt-Ingram Cancer Center
University of Iowa
Guangdong Provincial People's Hospital
Guangdong Provincial People's Hospital
Albert Einstein College of Medicine
Wake Forest University Health Sciences
University of Nebraska
National Cancer Institute (NCI)
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)
Guangdong Provincial People's Hospital
OHSU Knight Cancer Institute
Nektar Therapeutics
Sichuan Cancer Hospital and Research Institute
Shanghai Chest Hospital
Emory University
NextCure, Inc.
University of Washington
Emory University
AIDS Malignancy Consortium
Kobe Minimally Invasive Cancer Center
National Cancer Institute (NCI)
Masonic Cancer Center, University of Minnesota
Ohio State University Comprehensive Cancer Center
Alliance for Clinical Trials in Oncology